W. Robert Fleischmann - AHC - Virology, University of Minnesota

Return to: Academic Health Center : U of M Home

	MyU \| One Stop \| Directories \| Search U of M

What's Inside

IMV Home


	Home > Investigators > Core Investigators > W. Robert Fleischmann

W. Robert Fleischmann

Professor

Department of Urologic Surgery & Department of Microbiology

Email: rfleisch@umn.edu
Phone: (612) 626-5034

Education

Ph.D., Purdue University, Department of Biological Sciences, 1972

Research Interests

Development of a whole-cell tumor immunotherapy for melanoma; development of a whole-cell tumor immunotherapy for prostate cancer.

Selected Recent Publications

Fleischmann, W.R. Jr. Interferons in antitumor therapy: Current status and future prospects. Zdravniski Vestnik 63 (Suppl II):15-18.
Koren, S. and Fleischmann, W.R. Jr. Chronobiology of the interferon system. Zdravniski Vestnik 63 (Suppl II):27-30. 1994.
Fleischmann, C.M., Stanton, G.J., and Fleischmann, W.R. Jr. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:805-812. 1996.
Fleischmann, W.R. Jr. Chapter 43. Viral Genetics. In: S. Baron (ed.). Medical Microbiology, 4th Edition. Galveston: University of Texas Medical Branch, 555-562. 1996.
Georgiades, J.A. and Fleischmann, W.R. Jr. Oral Application of Cytokines. Biotherapy 8:205-212. 1996.
Fleischmann, C.M., Wu, T.Y., and Fleischmann, W.R. Jr. B16 melanoma cells exposed in vitro to long-term IFN- treatment (B16 cells) as activators of host cell tumor immunity in mice. J. Interferon Cytokine Res. 17:37-43. 1997.
Arany, I., Fleischmann, C.M., Tyring, S.K., and Fleischmann, W.R. Jr. Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells. Biochem. Biophys. Res. Commun. 233:678-680. 1997.
Arany, I., Fleischmann, C.M., Tyring, S.K., and Fleischmann, W.R. Jr. Lack of mda-6/WAF1/CIP1-mediated inhibition of cyclin-dependent kinases in interferon- resistant murine B16 melanoma cells. Cancer Letters 119:237-240. 1997.
Fleischmann, W.R. Jr., Masoor, J., Wu, T.Y., and Fleischmann, C.M. Orally administered IFN- acts alone and in synergistic combination with intraperitoneally administered IFN- to exert an antitumor effect against B16 melanoma in mice. J. Interferon Cytokine Res. 18;17-20. 1998.
Wu, T.Y. and Fleischmann, W.R. Jr. Efficacy of B16 melanoma cells exposed in vitro to long-term IFN- treatment (B16 cells) as a tumor vaccine in mice. J. Interferon Cytokine Res., 18:829-839. 1998.
Beilharz, M.W. and Fleischmann, W.R. Jr. Guest Editors, Special Topics Issue: Oral Use of Interferons and Cytokines. J. Interferon and Cytokine Res. 19:813-979. 1999.
Houston, C.W., Dworkin, M., and Fleischmann, W.R. 20th Century Evolution of Microbiological Education. ASM News 61:366-369. 1999
Beilharz, M.W. and Fleischmann, W.R. Jr. Introduction. J. Interferon Cytokine Res. 19:815. 1999.
Fleischmann, W.R. Jr. and Koren, S. Systemic effect of orally administered interferons and interleukin-2. J. Interferon Cytokine Res. 19:829-839. 1999.
Wu, T.Y. and Fleischmann, W.R. Jr. Murine B16 melanoma vaccination-induced tumor immunity: Identification of specific immune cells and functions involved. J. Interferon Cytokine Res., 21:1117-1127. 2001.
Fleischmann, W.R. Jr. and Wu, T.G. Development of a vaccine against cancers. Medicinski Razgledi 43 (suppl. 5):51-61. 2004.
Fleischmann, W.R. Jr. and Wu, T.G. Development of an interferon-based cancer vaccine protocol: application to several types of murine cancers. In: D.J.J. Carr (ed.) Interferon Methods and Protocols, Totowa: Humana Press, 151-166. 2005.
Wu, T.G., Rose, W.A., Albrecht, T.B., Knutson, E.P., Konig, R., Perdigao, J.R., Nguyen, A.P.A., and Fleischmann, W.R. Jr. IFN--induced murine B16 cancer vaccine cells: induction and accumulation of cell-associated IL-15. J. Interferon Cytokine Res. 27: 13-22. 2007.
Fleischmann, W.R. Jr. and Wu,T.G. Interferons and cancer: From interferon treatment to the use of interferon-treated cancer cells as vaccines. Invited review, in press.
Fleischmann, W.R. Jr., Koren, S., and Wu, T.G. Oral administration of interferons. Invited review, in press.
Morais, M.C., K.H.Choi, J.S. Koti, P.R. Chipman, D.L. Anderson and M.G. Rossmann. 2005. Conservation of the capsid structure in tailed dsDNA bacteriophages: the pseudoatomic structure of ?29. Mol. Cell 18:149-159.
Chemla, Y. R. Aathavan, K. Michaelis, J. Grimes, S. Jardine, P. J. Anderson, D.L. Bustamante, C. 2005. Mechanism of force generation of a viral DNA packaging motor. Cell 122: 683-692.
Anderson, D. and S. Grimes. 2004. The ø29 DNA packaging motor: seeking the mechanism. In Viral Genome Packaging. C. Catalano, ed., Landes Bioscience, Chapter 7.
Morais, M. C., S. Kanamaru, M. O. Badasso, J. S. Koti, B. A. L. Owen, C. T. McMurray, D .L.. Anderson, and M. G. Rossmann. 2003. Bacteriophage phi29 scaffolding protein gp7 before and after prohead assembly. Nature Struct. Biol. 10:572-576.
Wang, H., S. Grimes, D.L. Anderson and P. Serwer. 2003. Terminal protein-induced stretching of bacteriophage ø29 DNA. J. Microscopy 213:172-179.
Grimes, S., P. J. Jardine, and D. Anderson. 2002. Bacteriophage ø29 DNA packaging. Adv. Virus Res.58:255-294.

Feedback | Notice of Privacy Practices